novartis ag-2nd line
(NOVNEE:SIX Swiss Ex)
Transactions by NOVARTIS AG-2ND LINE (NOVNEE) in the last 6 months
Novartis AG (SWX:NOVN) exercised its option to acquire exclusive license for development and worldwide commercialization of CAM2029 from Camurus for $700 million on September 10, 2013. The exercise of the option triggers an undisclosed milestone payment to Camurus from eligible potential payments of up to $700 million, subject to achievement of predefined development, regulatory and commercial milestones for the products included in the agreement. In addition, Camurus ...
Ensemble Therapeutics Corporation announced that it will receive its seventh round of funding form Novartis on August 6, 2013. The terms of the transaction were undisclosed. The company will also receive also receive research funding from as well as tiered royalties on potential future sales of products that may result from the collaboration from the investor.
|Johnson & Johnson||$91.16 USD||-1.95|
|Nestle SA||SFr.63.50 CHF||-0.30|
|Pfizer Inc||$30.25 USD||0.00|
|Roche Holding AG||SFr.234.70 CHF||-1.50|
|Procter & Gamble Co/The||$82.30 USD||-1.72|
|View Industry Companies|
Post a JobJobs
- Pittsburgh, PA | Carnegie Museums of PittsburghPosted: Dec 09
- New York, NY | JPMorgan ChasePosted: Dec 06
- Alexandria, VA |Posted: Dec 06
- Detroit, MI | Wayne State UniversityPosted: Nov 26